Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25026639 | 0.98 | NCF1 (0.43) | NCF1CHRM5ADRA2CACHECACNA2D1 | |
| SCHEMBL27268712 | 0.93 | CXCR4 (0.47) | NCF1CHRM5ADRA2CACHECACNA2D1 | |
| SCHEMBL23874494 | 0.90 | ACHE (0.40) | NCF1CHRM5ADRA2CACHECACNA2D1 | |
| SCHEMBL18883293 | 0.90 | NCF1 (0.39) | NCF1CHRM5ADRA2CACHECACNA2D1 | |
| SCHEMBL25074009 | 0.90 | NCF1 (0.39) | NCF1CHRM5ADRA2CACHECACNA2D1 | |
| SCHEMBL25027122 | 0.89 | NCF1 (0.37) | NCF1CHRM5ADRA2CACHECACNA2D1 | |
| SCHEMBL25856575 | 0.89 | NCF1 (0.37) | NCF1CHRM5ADRA2CACHECACNA2D1 | |
| SCHEMBL24480857 | 0.86 | ACHE (0.40) | NCF1CHRM5ADRA2CACHEGBA1 | |
| SCHEMBL21094260 | 0.85 | RAD52 (0.38) | NCF1CHRM5ADRA2CACHECACNA2D1 | |
| SCHEMBL24480754 | 0.84 | GBA1 (0.36) | NCF1CHRM5ADRA2CACHECACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI, INC. (KR) | 2025-12-04 | — | — | US | claimed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024112692-A1 | CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024044334-A2 | METHODS AND COMPOSITIONS FOR MODULATING KRAS(G12D) | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-18 | — | — | US | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458375-A2 | COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003051842-A2 | COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | NCF1 2943/4885CHRM5 383/4885ADRA2C 380/4885 |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | NCF1 3483/4885CHRM5 4828/4885ADRA2C 4358/4885 |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | NCF1 2352/4885CHRM5 428/4885ADRA2C 191/4885 |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | NCF1 1440/4885CHRM5 3514/4885ADRA2C 2115/4885 |
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | ERBB2, EGFR, ERBB3 | NCF1 1377/4885CHRM5 4679/4885ADRA2C 2836/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | NCF1 1332/4885CHRM5 2810/4885ADRA2C 1723/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | NCF1 3483/4885CHRM5 4828/4885ADRA2C 4358/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | NCF1 2943/4885CHRM5 383/4885ADRA2C 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.